1. Brooke Story appointed Chairman of PolyPid's Board of Directors. 2. Her experience in surgical market will aid commercial success. 3. D-PLEX100 New Drug Application submission is expected in early 2026. 4. PolyPid aims to improve surgical outcomes with innovative therapeutics. 5. The company's pipeline targets obesity, diabetes, and oncology.
FAQ
Why Bullish?
The appointment of an experienced leader can drive operational efficiency and commercial success. Historical examples show that strong leadership positively correlates with stock performance, especially before significant product launches.
How important is it?
Leadership appointments in biopharma, especially with experience in relevant sectors, heighten investor confidence and are crucial during pivotal company developments.
Why Short Term?
The imminent NDA submission for D-PLEX100 can impact stock prices quickly. Market reactions are commonly seen ahead of product approvals.
PolyPid Appoints Brooke Story as Chairman of the Board of Directors
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has announced the appointment of Brooke Story as the new Chairman of the Board of Directors. This strategic move, effective December 11, 2025, positions the company for growth as it prepares for the upcoming submission of its New Drug Application (NDA) for D-PLEX₁₀₀.
Strategic Appointment Enhances Company Leadership
Brooke Story's appointment is seen as a pivotal moment for PolyPid. According to Dikla Czaczkes Akselbrad, CEO of PolyPid, "Brooke’s global expertise in the surgical market and infection prevention, paired with her extensive experience in corporate strategy, will be instrumental in transforming our clinical successes into commercial realities."
With over 25 years of leadership in the MedTech industry, Story has held significant roles at notable companies such as BD (Becton, Dickinson and Company) and Medtronic PLC. As the former Worldwide President of BD’s Surgery business, she managed the global strategy and profit & loss for portfolios that include hernia repair, tissue repair, and infection prevention.
Future Focus: Surgical Infection Prevention
Story highlighted her enthusiasm for joining PolyPid, stating, "I am honored to join PolyPid at this pivotal stage in the Company’s development. I look forward to supporting the team in leveraging its delivery platform to tackle pressing high-cost challenges in surgical infection prevention."
This focus aligns with PolyPid’s mission to create considerable enterprise value and deliver transformative healthcare solutions. Story's extensive background in mergers and acquisitions will also support PolyPid's future growth strategies.
About PolyPid and D-PLEX₁₀₀
PolyPid (Nasdaq: PYPD) aims to improve surgical outcomes through its innovative therapeutic technologies. Notably, the company’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology allows for precise delivery of medications at optimal release rates, improving patient care across various surgical contexts.
Following promising results from phase 3 trials, the NDA submission for D-PLEX₁₀₀, aimed at preventing abdominal colorectal surgical site infections, is anticipated in early 2026. The company also has a robust pipeline targeting oncology, obesity, and diabetes.
Leadership and Vision
In addition to her role at PolyPid, Story is a non-executive director on the board of LivaNova PLC and has previously served on the boards of Sigilon Therapeutics, Inc. and as a board observer for Avation Medical, Inc.. With a Bachelor of Science in Engineering from the University of Tennessee and an MBA from the University of Michigan, her leadership is expected to guide PolyPid through its next chapter of innovation and growth.
Looking Ahead
This new leadership structure at PolyPid positions the company favorably within the competitive landscape of the biopharma industry. Investors and stakeholders can look forward to a potential boost in both operations and financial performance as the company leverages its new strategic direction under the guidance of Brooke Story.